GRAND RAPIDS, Mich., Aug. 28, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the second quarter of 2025 before market open on Tuesday, September 9, 2025.
On the same day, members of management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place at 8:30 a.m. ET / 5:30 a.m. PT on September 9, 2025.
A live and archived version of the fireside chat will be available on the "Investor Relations" section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.
About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.
Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.05 |
| Daily Change: | -0.17 -1.52 |
| Daily Volume: | 39,121 |
| Market Cap: | US$349.840M |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
